Targets › HPV5
2 programs from 2 companies in 2 trials: 2 Phase 4; Infectious disease, Genitourinary; next expected readout Aug 2027.
Open in Phaseline: the race on HPV5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Medical Branch, Galveston | 9-valent HPV vaccine, 2 doses alternate timing Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV5, HPV6, HPV11, HPV16, HPV18 | Phase 4 | Immunization | Aug 2027 |
| Erasmus Medical Center | Gardasil 9 Suspension for Injection Nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 | HPV5, HPV11, HPV16, HPV18 | Phase 4 | Vulvar HSIL | Dec 2028 |
Immunization (1) Vulvar HSIL (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.